Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 1, 2026 | Capital Blue Cross | Bone Turnover Markers TestingPayerPolicy · CAPBLUE-AHS-–-G2051 | New policy |
|---|
| Aug 1, 2026 | Capital Blue Cross | Biomarker Testing for Multiple Sclerosis and Related Neurologic DiseasesPayerPolicy · CAPBLUE-AHS-–-G2123 | New policy |
|---|
| Aug 1, 2026 | Capital Blue Cross | Biomarker Testing for Autoimmune Rheumatic DiseasePayerPolicy · CAPBLUE-AHS-–-G2022 | New policy |
|---|
| Aug 1, 2026 | Capital Blue Cross | Biomarkers for Myocardial Infarction and Chronic Heart FailurePayerPolicy · CAPBLUE-AHS-–-G2150 | New policy |
|---|
| Aug 1, 2026 | Capital Blue Cross | β-Hemolytic Streptococcus TestingPayerPolicy · CAPBLUE-AHS-–-G2159 | New policy |
|---|
| Aug 1, 2026 | Capital Blue Cross | Photocoagulation Therapy for Treatment of AMDPayerPolicy · CAPBLUE-MP-4.008 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Vagus Nerve Blocking Therapy for the Treatment of ObesityPayerPolicy · CAPBLUE-MP-1.146 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Spinal Cord and Dorsal Root Ganglion StimulationPayerPolicy · CAPBLUE-MP-1.069 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Intravenous Antibiotic Therapy for Lyme DiseasePayerPolicy · CAPBLUE-MP-2.026 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Interventions for Progressive ScoliosisPayerPolicy · CAPBLUE-MP-1.120 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Implantable Infusion Pumps for Pain and SpasticityPayerPolicy · CAPBLUE-MP-1.058 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Molecular Testing for Germline Variants Associated with Ovarian Cancer (BRIP1, RAD51C, RAD51D, NBN)PayerPolicy · CAPBLUE-MP-2.377 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Germline Genetic Testing for Gene Variants Associate with Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1)PayerPolicy · CAPBLUE-MP-2.279 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Wound and Burn Management and Specialized Treatment CentersPayerPolicy · CAPBLUE-MP-4.028 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic DisordersPayerPolicy · CAPBLUE-MP-2.324 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Whole Body Dual X-Ray Absorptiometry to Determine Body CompositionPayerPolicy · CAPBLUE-MP-5.037 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Vertical Expandable Prosthetic Titanium RibPayerPolicy · CAPBLUE-MP-1.136 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Vagus Nerve and Implantable Peripheral Nerve StimulatorsPayerPolicy · CAPBLUE-MP-1.034 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Use of Common Genetic Variants (Single Nucleotide Polymorphisms) to Predict Risk of Non-Familial Breast CancerPayerPolicy · CAPBLUE-MP-2.249 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Tumor Treating Fields TherapyPayerPolicy · CAPBLUE-MP-6.054 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Trigger Point and Tender Point InjectionsPayerPolicy · CAPBLUE-MP-2.072 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Treatment of Varicose Veins - Venous InsufficiencyPayerPolicy · CAPBLUE-MP-1.061 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Treatment of Dry Eye SyndromePayerPolicy · CAPBLUE-MP-4.033 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Transmyocardial RevascularizationPayerPolicy · CAPBLUE-MP-1.057 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Threshold Electrical Stimulation as a Treatment of Motor DisordersPayerPolicy · CAPBLUE-MP-6.046 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Thermal Capsulorrhaphy as a Treatment of Joint InstabilityPayerPolicy · CAPBLUE-MP-1.086 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Temporomandibular DisorderPayerPolicy · CAPBLUE-MP-2.062 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Surgical Ventricular RestorationPayerPolicy · CAPBLUE-MP-1.082 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Surgical Treatments for Breast Cancer Related LymphedemaPayerPolicy · CAPBLUE-MP-1.161 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Surgical Treatment of GynecomastiaPayerPolicy · CAPBLUE-MP-1.129 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Surgery for Groin Pain in AthletesPayerPolicy · CAPBLUE-MP-1.163 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Subtalar ArthroereisisPayerPolicy · CAPBLUE-MP-1.114 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Steroid-Eluting Sinus Stents and ImplantsPayerPolicy · CAPBLUE-MP-1.140 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Stem Cell Therapy for Peripheral Arterial DiseasePayerPolicy · CAPBLUE-MP-2.089 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Somatic Genetic Testing to Select Individuals with Melanoma or Glioma for Targeted Therapy or ImmunotherapyPayerPolicy · CAPBLUE-MP-2.364 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment of Metastatic Colorectal Cancer (KRAS, NRAS, BRAF, NTRK, and HER2)PayerPolicy · CAPBLUE-MP-2.316 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Somatic Biomarker Testing For Immune Checkpoint Inhibitor Therapy (MSIMMR, PD-L1, TMB)PayerPolicy · CAPBLUE-MP-2.388 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Therapy in Non-Small Cell LungPayerPolicy · CAPBLUE-MP-2.241 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Serum Biomarkers for Human Epididymis Protein 4 (HE4)PayerPolicy · CAPBLUE-MP-2.269 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Serum Antibody Markers for Diagnosing Inflammatory Bowel DiseasePayerPolicy · CAPBLUE-MP-2.222 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Sensory Integration Therapy and Auditory Integration TherapyPayerPolicy · CAPBLUE-MP-8.011 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Semi-Implantable and Fully Implantable Middle Ear Hearing AidPayerPolicy · CAPBLUE-MP-1.130 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Sacral Nerve Neuromodulation-StimulationPayerPolicy · CAPBLUE-MP-1.033 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Responsive Neurostimulation for the Treatment of Refractory Focal EpilepsyPayerPolicy · CAPBLUE-MP-1.156 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Reduction Mammoplasty for Breast-Related SymptomsPayerPolicy · CAPBLUE-MP-1.013 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Recombinant and Autologous Platelet Derived Growth Factors as a Treatment of Wound Healing and Other Non-Orthopedic ConditionsPayerPolicy · CAPBLUE-MP-2.033 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Radiofrequency Ablation of Thyroid TumorsPayerPolicy · CAPBLUE-MP-1.165 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver TumorsPayerPolicy · CAPBLUE-MP-1.084 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung CancerPayerPolicy · CAPBLUE-MP-2.337 | Metadata changed |
|---|
| Aug 1, 2026 | Capital Blue Cross | Proteogenomic Testing for Patients With CancerPayerPolicy · CAPBLUE-MP-2.343 | Metadata changed |
|---|